Saad Usmani to Retrospective Studies
This is a "connection" page, showing publications Saad Usmani has written about Retrospective Studies.
Connection Strength
1.062
-
Firestone RS, McAvoy D, Shekarkhand T, Serrano E, Hamadeh I, Wang A, Zhu M, Qin WG, Patel D, Tan CR, Hultcrantz M, Mailankody S, Hassoun H, Shah US, Korde N, Maclachlan KH, Landau HJ, Scordo M, Shah GL, Lahoud OB, Giralt S, Murata K, Hosszu KK, Chung DJ, Lesokhin AM, Usmani SZ. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -na?ve multiple myeloma. Blood Adv. 2024 04 09; 8(7):1600-1611.
Score: 0.094
-
Hamadeh IS, Moore DC, Martin A, Karabinos A, Hill H, Ndiaye A, Robinson JD, Paul BA, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice. Clin Lymphoma Myeloma Leuk. 2021 07; 21(7):470-475.
Score: 0.076
-
Hamadeh IS, Reese ES, Arnall JR, Kachur E, Martin AL, Schneider M, Friend R, Paul B, Atrash S, Bhutani M, Voorhees PM, Usmani SZ. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. Clin Lymphoma Myeloma Leuk. 2020 08; 20(8):526-532.e1.
Score: 0.071
-
Arnall JR, Moore DC, Hill HL, Griffin S, Mueller MK, Lavery LA, Voorhees PM, Usmani SZ. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses. Leuk Lymphoma. 2019 09; 60(9):2295-2298.
Score: 0.066
-
Li S, Natwick T, Liu J, Morrison VA, Vidito S, Werther W, Yusuf AA, Usmani SZ. Mortality by a proxy performance status as defined by a claims-based measure for disability status in older patients with newly diagnosed multiple myeloma in the United States. J Geriatr Oncol. 2019 05; 10(3):490-496.
Score: 0.066
-
Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematol. 2017 Sep; 4(9):e443-e451.
Score: 0.060
-
Arikian SR, Milentijevic D, Binder G, Gibson CJ, Hu XH, Nagarwala Y, Hussein M, Corvino FA, Surinach A, Usmani SZ. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma. Curr Med Res Opin. 2015 Jun; 31(6):1105-15.
Score: 0.051
-
Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D, Barlogie B, Usmani SZ. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):211-4.
Score: 0.046
-
Usmani SZ, Heuck C, Mitchell A, Szymonifka J, Nair B, Hoering A, Alsayed Y, Waheed S, Haider S, Restrepo A, Van Rhee F, Crowley J, Barlogie B. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012 Nov; 97(11):1761-7.
Score: 0.042
-
Adegbite B, Tan CR, Shekarkhand T, Firestone RS, Jurgens EM, Miller K, Lesokhin AM, Shah GL, Korde N, Rajeeve S, Landau HJ, Scordo M, Hassoun H, Maclachlan KH, Shah UA, Hultcrantz M, Hamadeh IS, Derkach A, Nemirovsky D, Giralt SA, Mailankody S, Usmani SZ, Hashmi H. Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma. Blood Adv. 2025 Aug 12; 9(15):4016-4022.
Score: 0.026
-
Einarsdottir S, Lobaugh S, Luan D, Gomez-Llobell M, Subramanian P, Devlin S, Chung D, Dahi PB, Falchi L, Giralt S, Landau H, Lesokhin AM, Lin R, Lue J, Mailankody S, Palomba ML, Park JH, Salles G, Scordo M, Escribano-Serrat S, Sanz J, Rejeski K, Shouval R, Usmani S, Perales MA, Shah G, Shahid Z. Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies. Blood Cancer J. 2025 Jul 02; 15(1):114.
Score: 0.026
-
Tan CR, Asoori S, Huang CY, Brunaldi L, Popat R, Kastritis E, Martinez-Lopez J, Bansal R, Silva Corraes AM, Chhabra S, Parrondo R, Ailawadhi S, Fotiou D, Dimopoulos MA, Yong K, Mactier C, Lau C, Corona M, Marin AJS, Mian H, Durie BG, Usmani SZ, Martin TG, Lin Y. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 2025 Apr 03; 15(1):53.
Score: 0.025
-
Shaffer BC, Brown S, Chinapen S, Mangold KE, Lahoud O, Lopez-Jimenez F, Schaffer W, Liu J, Giralt S, Devlin S, Shah G, Scordo M, Papadopoulos E, Landau H, Usmani S, Perales MA, Friedman PA, Gersh BJ, Attia IZ, Noseworthy PA, Kosmidou I. Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity. Blood Adv. 2024 11 12; 8(21):5603-5611.
Score: 0.025
-
Hamadeh IS, Shekarkhand T, Rueda C, Firestone RS, Wang AX, Korde N, Hultcrantz ML, Lesokhin AM, Mailankody S, Hassoun H, Shah UA, Maclachlan K, Rajeeve S, Patel D, Shah GL, Scordo M, Lahoud OB, Chung DJ, Landau HJ, Giralt S, Usmani SZ, Tan CR. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy. Blood Adv. 2024 06 25; 8(12):3038-3044.
Score: 0.024
-
Howard AJ, Concepcion I, Wang AX, Hamadeh IS, Hultcrantz M, Mailankody S, Tan C, Korde N, Lesokhin AM, Hassoun H, Shah UA, Maclachlan KH, Rajeeve S, Landau HJ, Scordo M, Shah GL, Lahoud OB, Chung DJ, Giralt S, Usmani SZ, Firestone RS. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies. Blood Adv. 2024 06 25; 8(12):3246-3253.
Score: 0.024
-
Nath K, Shekarkhand T, Nemirovsky D, Derkach A, Costa BA, Nishimura N, Farzana T, Rueda C, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Korde N, Shah UA, Tan CR, Hultcrantz M, Giralt SA, Usmani SZ, Shahid Z, Mailankody S, Lesokhin AM. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024 05 31; 14(1):88.
Score: 0.024
-
Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, Chung DJ, Landau HJ, Lahoud OB, Scordo M, Shah GL, Hassoun H, Maclachlan K, Hultcrantz M, Korde N, Lesokhin AM, Shah UA, Tan CR, Giralt SA, Usmani SZ, Nath K, Mailankody S. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024 05 27; 14(1):84.
Score: 0.024
-
Shah UA, Moshier E, Derkach A, Huang Y, Mailankody S, Tan CR, Maclachlan K, Hultcrantz M, Korde N, Hassoun H, Thibaud S, Sanchez L, Rodriguez C, Richard S, Richter J, Rossi A, Cho HJ, Lesokhin A, Chari A, Usmani SZ, Jagannath S, Parekh S, Gallagher EJ. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups. Blood Adv. 2024 01 09; 8(1):236-247.
Score: 0.023
-
Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Genomic Classification and Individualized Prognosis in Multiple Myeloma. J Clin Oncol. 2024 Apr 10; 42(11):1229-1240.
Score: 0.023
-
Htut M, Dhakal B, Cohen AD, Martin T, Berdeja JG, Usmani SZ, Agha M, Jackson CC, Madduri D, Deraedt W, Zudaire E, Yeh TM, Xu X, Pacaud L, Akram M, Jagannath S. Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study. Clin Lymphoma Myeloma Leuk. 2023 12; 23(12):882-888.
Score: 0.023
-
Tan CR, Derkach A, Nemirovsky D, Ciardiello A, Diamond B, Hultcrantz M, Hassoun H, Mailankody S, Shah U, Maclachlan K, Patel D, Lahoud OB, Landau HJ, Chung DJ, Shah GL, Scordo M, Giralt SA, Lesokhin A, Usmani SZ, Landgren O, Korde N. Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma. Blood Cancer J. 2023 07 25; 13(1):112.
Score: 0.022
-
Atrash S, Robinson M, Taneja A, Paul B, Cassetta K, Ndiaye A, Varga C, Block J, Lipford EH, Smith ET, McCall CM, Thurston V, Foureau D, Usmani SZ, Voorhees PM, Bhutani M. Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma. Eur J Haematol. 2023 Sep; 111(3):373-381.
Score: 0.022
-
Pianko MJ, Tiutan T, Derkach A, Flynn J, Salvatore SP, Jaffer-Sathick I, Rossi AC, Lahoud O, Hultcrantz M, Shah UA, Maclachlan K, Chung DJ, Shah GL, Landau HJ, Korde N, Mailankody S, Lesokhin AM, Tan C, Scordo M, Jaimes EA, Giralt SA, Usmani S, Hassoun H. Assessment of renal outcome following therapy in monoclonal immunoglobulin deposition disease: Emphasizing the need for a consensus approach. Am J Hematol. 2023 03; 98(3):421-431.
Score: 0.022
-
Blad? J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, Rasche L, Rosi?ol L, Usmani SZ, Zamagni E, Richardson P. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022 03 21; 12(3):45.
Score: 0.020
-
Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, Touzeau C, Bahlis NJ, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner CP, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukropec J, Pei H, Van Rampelbergh R, Uhlar CM, Kobos R, Zweegman S. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022 04; 36(4):1066-1077.
Score: 0.020
-
Fern?ndez de Larrea C, Kyle R, Rosi?ol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M, Miguel JS, Blad? J, Rajkumar SV, Mateos MV. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021 12 02; 11(12):192.
Score: 0.020
-
Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients. Bone Marrow Transplant. 2022 02; 57(2):295-298.
Score: 0.020
-
Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021 Sep; 100(9):2325-2337.
Score: 0.019
-
Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, Lam A, Ukropec J, Maiese EM, Nair S, Potluri R, Voorhees PM. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020 Nov 10; 20(1):1087.
Score: 0.019
-
Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb; 23(2):269-277.
Score: 0.014
-
Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2016 10; 22(10):1893-1899.
Score: 0.014
-
Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. Am J Hematol. 2016 06; 91(6):575-80.
Score: 0.014